Abstracts tagged "autoimmune diseases"

Abstract Number: 1634 • ACR Convergence 2023
Iscalimab (CFZ533) in Patients with Sjögren’s Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
Benjamin A Fisher¹, Xavier Mariette², Athena S Papas³, Thomas Grader-Beck⁴, Hendrika Bootsma⁵, Wan-Fai Ng⁶, Paul Van Daele⁷, Stephanie Finzel⁸, Sergio Elgueta⁹, Josef Hermann¹⁰, Sara McCoy¹¹, Arthur Bookman¹², Monika Sopala¹³, Wen-Lin Luo¹⁴, Cornelia Scheurer¹³ and Wolfgang Hueber¹³, ¹University of Birmingham, Birmingham, United Kingdom, ²Université Paris-Saclay, Le Kremlin-Bicêtre, France, ³Division of Oral Medicine, Tufts School of Dental Medicine, Boston, MA, ⁴Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁵Department of Rheumatology, University Medical Centre Groningen, Groningen, Netherlands, ⁶NIHR Newcastle Clinical Research Facility, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁷Department of internal medicine, Erasmus MC, Rotterdam, Netherlands, ⁸Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, ⁹Clinical Research Chile SpA, Biomedical Research Centre, Valdivia, Chile, ¹⁰Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, ¹¹University of Wisconsin School of Medicine and Public Health, Middleton, WI, ¹²Toronto Western Hospital, Toronto, ON, Canada, ¹³Novartis Pharma AG, Basel, Switzerland, ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Sjögren's disease (SjD) is an autoimmune disease affecting secretory glands and other organs with no approved systemic treatments. Iscalimab (CFZ533) is a mAb directed…
Abstract Number: 1801 • ACR Convergence 2023
Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study
Ioanna Minopoulou¹, Koray Tascilar², Giulia Corte¹, Melek Yalcin Mutlu¹, Katja Schmidt², Daniela Bohr¹, Fabian Hartmann², Bernhard Manger², Arnd Kleyer³, David Simon¹, Thomas Harrer², Georg Schett⁴ and Filippo Fagni¹, ¹Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Hospital Erlangen, Erlangen, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) and particularly those treated with B-cell-depleting agents frequently fail to develop humoral responses to SARS-CoV-2 vaccinations and have…
Abstract Number: 1937 • ACR Convergence 2023
Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis
Frank Cai¹, Anisha Paulson¹, Amy Wozniak², Emily Gilbert² and Rochella Ostrowski², ¹Loyola University Medical Center, Oak Park, IL, ²Loyola University Medical Center, Maywood, IL
Background/Purpose: There is currently a lack of a consensus standardized guideline for the treatment of cardiac sarcoidosis (CS) because of its rarity, heterogeneity of disease…
Abstract Number: 2158 • ACR Convergence 2023
Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Mueller⁶, Steven Sambevski⁷ and Wim A Wuyts⁸, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁸Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital capacity (FVC) compared with placebo,…
Abstract Number: 2463 • ACR Convergence 2023
Efficacy and Safety of Car-T-Cell Treatment in Refractory Antisynthetase Syndrome – Data of the First Three Patients
Jule Taubmann¹, Johannes Knitza², Fabian Müller³, Sebastian Boeltz¹, Simon Voelkl⁴, Michael Aigner⁴, Arnd Kleyer⁵, Ioanna Minnopoulou¹, Regina Gary⁴, Sascha kretschmann⁴, Andreas Mackensen⁴ and Georg Schett⁶, ¹Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ²Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ³Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany, ⁶Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Antisynthetase syndrome (ASS) can be very severe affecting the lungs, the skin and the joints next to the muscles. ASS can take a refractory…
Abstract Number: PP12 • ACR Convergence 2023
Sjögren’s-Fatigue: Non-Therapeutic Lifestyle Adjustments to Help Manage My Most Problematic Symptom
Susan Barajas, Sjögren's Foundation, Los Angeles, CA
Background/Purpose: I was diagnosed with Sjögren's disease in 2015. I sought help from a rheumatologist after experiencing hand pain. I also had dry eyes and…
Abstract Number: 0032 • ACR Convergence 2023
Quantification of the Escape from X Chromosome Inactivation with the Million Cell-scale Human Blood Single-cell RNA-seq Datasets Reveals Heterogeneity of Escape Across Immune Cells and Escape in the Autoimmune Disease Conditions
Yoshihiko Tomofuji¹, Ryuya Edahiro¹, Yuya Shirai¹, Kyuto Sonehara², Qingbo Wang¹, Atsushi Kumanogoh¹ and Yukinori Okada³, ¹Osaka University, Suita, Japan, ²University of Tokyo, Tokyo, Japan, ³University of Tokyo / Osaka University / RIKEN, Tokyo, Japan
Background/Purpose: Understanding the differences in the immune system between sexes is important to elucidate the pathogenesis of autoimmune diseases which are more prevalent in females…
Abstract Number: 0097 • ACR Convergence 2023
Transient Ischemic Attack in Antiphospholipid Antibody-positive Patients: Retrospective and Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Jonathan Thaler², Danieli Andrade³, Megan Barber⁴, Maria Tektonidou⁵, Savino Sciascia⁶, Vittorio Pengo⁷, Jose Pardos-Gea⁸, Guillermo Ruiz-Irastorza⁹, Chary Lopez-Pedrera¹⁰, H Michael Belmont¹¹, Kello Nina¹², Paul R. Fortin¹³, Stéphane Zuily¹⁴, Cecilia Chighizola¹⁵, Flavio Victor Signorelli¹⁶, Zhuoli Zhang¹⁷, Tatsuya Atsuma¹⁸, Maria Efthymiou¹⁹, D. Ware Branch²⁰, Cecilia Nalli²¹, Esther Rodriguez almaraz²², Michelle Petri²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Yu Zuo²⁸, Rosana M Quintana²⁹, Rohan Willis³⁰, Ali Duarte-Garcia³¹, Maria Laura Bertolaccini³², Hannah Cohen³³, Doruk Erkan² and On Behalf Of APS ACTION³⁴, ¹SUNY Downstate Medical Center, Brooklyn, NY, ²Hospital for Special Surgery, New York, NY, ³University of São Paulo, São Paulo, Brazil, ⁴University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁵Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶University of Turin, Torino, Italy, ⁷Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Hospital Universitario Cruces, Barakaldo, Spain, ¹⁰IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Northwell Health, Brooklyn, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁴Lorraine University, Vandoeuvre-lès-Nancy, France, ¹⁵University of Milan, Milan, Italy, ¹⁶University of São Paulo, Rio De Janeiro, Brazil, ¹⁷Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁸Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ¹⁹University College London, London, United Kingdom, ²⁰University of Utah, Salt Lake City, UT, ²¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷Rijin Hospital, Shanghai, China, ²⁸University of Michigan, Ann Arbor, MI, ²⁹Centro Regional de Enfermedades Autoinmunes y Reumticas (CREAR), Grupo Oroño, Rosario, Argentina, ³⁰University of Texas Medical Branch, Galveston, TX, ³¹Mayo Clinic, Rochester, MN, ³²King's College London, London, United Kingdom, ³³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³⁴on behalf of APS ACTION, New York, NY
Background/Purpose: APS ACTION Registry aims to study the course of disease in antiphospholipid antibody (aPL)-positive patients. Although transient ischemic attack (TIA) can develop in aPL-positive…
Abstract Number: 0221 • ACR Convergence 2023
Post-COVID-19 Autoimmune Serologies and Immunophenotypes
Emily G. Oakes¹, Katherine Buhler², Ifeoluwakiisi Adejoorin¹, Kathryne Marks¹, Eilish Dillon¹, Jack Ellrodt¹, Jeong Yee¹, Deepak Rao¹, May Choi³ and Karen Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²University of Calgary; Cumming School of Medicine, Calgary, AB, Canada, ³University of Calgary, Calgary, AB, Canada, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Autoimmunity after COVID-19 infection has been reported. We examined connective tissue disease (CTD) symptoms and autoantibodies, SARS-CoV-2 serologies, and T and B cell immunophenotypes…
Abstract Number: 0412 • ACR Convergence 2023
COVID Antibody Response to Third Dose Anti-SARS-COV2 mRNA Vaccine in Patients with Seropositive Rheumatoid Arthritis on Immunosuppressive Therapy
Karthik Kovuru¹, Sylwia Waz¹ and Aarti Malik², ¹University of Chicago (Northshore) Internal Medicine Residency, Chicago, IL, ²Department of Rheumatology, University of Chicago/Northshore University, Chicago, IL
Background/Purpose: Patients with immune-mediated inflammatory diseases on immunosuppressive medications are presumed to be at increased risk for hospital admissions and deaths related to COVID-19 infections.…
Abstract Number: 0592 • ACR Convergence 2023
Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Martin Aringer¹, Laurent Arnaud², Richard A. Furie³, Eric Morand⁴, Christine Peschken⁵, Barnabas Desta⁶, Eleni Rapsomaniki⁷, Jonatan Hedberg⁸, Tina Grünfeld Eén⁸, Alessandro Sorrentino⁹, Canna Ghia⁹, Stephanie Chen¹⁰ and Bo Ding⁸, ¹Faculty of Medicine TU Dresden, Dresden, Germany, ²University Hospitals of Strasbourg, Strasbourg, France, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁸BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁹Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ¹⁰BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: The international SLE Prospective Observational Cohort Study (SPOCS) collected data on patients with moderate to severe SLE disease activity from June 2017 through November…
Abstract Number: 0829 • ACR Convergence 2023
Decreased History of Breastfeeding During Infancy in Juvenile Spondyloarthritis: A Case-Control Study
Katelyn Baggett¹, Timothy G. Brandon², Rui Xiao³ and Pamela F. Weiss⁴, ¹Penn State College of Medicine, Newtown Square, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Department of Pediatrics Division of Biostatistics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The pathogenesis of juvenile spondyloarthritis (JSpA) is multifactorial, and includes a genetic predisposition of the HLA-B27 allele, and environmental exposures such as the microbiome.…
Abstract Number: 1052 • ACR Convergence 2023
Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking
Sokratis Apostolidis¹, Kyra Sacksith¹, Bria Fulmer¹, Zoe Quandt², Mark Anderson², Terri Laufer³ and E. John Wherry¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of California San Francisco, San Franscisco, CA, ³University of Pennsylvania, Philadlephia, PA
Background/Purpose: The use of anti-PD-1 (aPD-1) immunotherapy has seen significant success in clinical practice, corresponding with a continued rise in clinical indications for multiple cancer…
Abstract Number: 1149 • ACR Convergence 2023
Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series
Tessalyn Morrison¹, Taylor Lakusta-Wong¹, Chantal Roy-Hewitson¹, Jeanne Gosselin² and Alana Nevares³, ¹University of Vermont, Burlington, VT, ²University of Vermont Medical Center, Waterbury, VT, ³University of Vermont, Essex Junction, VT
Background/Purpose: Sarcoidosis is a systemic inflammatory disease characterized by non-necrotizing granuloma formation affecting the lung, lymphatics, heart, skin, eye, kidney, and, in neurosarcoidosis, the nervous…
Abstract Number: 1443 • ACR Convergence 2023
Vasculitis Associations Among Patients with Systemic Lupus Erythematous
Emily Cosentino¹, Mia Blanchard², Diane L. Kamen¹ and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, ²Claremont Graduate University, Claremont, CA
Background/Purpose: Vasculitis is rare manifestation of systemic lupus erythematous (SLE) that often leads to increased morbidity and mortality. Vasculitis prevalence in SLE patients have ranged…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].